Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The ACXP news feed on Stock Titan brings together company press releases, scientific updates and regulatory disclosures that highlight progress across its DNA polymerase IIIC (pol IIIC) inhibitor platform.
Readers can follow detailed announcements on ibezapolstat, Acurx’s lead oral Gram-Positive Selective Spectrum (GPSS®) antibiotic candidate for Clostridioides difficile Infection (CDI). News items include Phase 2 clinical data, preparations for international Phase 3 trials, and regulatory milestones such as FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, EMA scientific advice, and a positive opinion from the EMA Paediatric Committee on the Pediatric Investigation Plan for ibezapolstat in children.
The ACXP news stream also covers developments in Acurx’s preclinical DNA pol IIIC pipeline, including patents granted in multiple jurisdictions for the ACX-375C program, collaborations with Leiden University Medical Center (LUMC) on structural biology of pol IIIC, and presentations at major scientific meetings like IDWeek and other infectious disease conferences. These updates often describe new data on microbiome selectivity, bile acid profiles, and potential class effects across the company’s inhibitor series.
Investors and observers can track capital markets and corporate actions reported by Acurx, such as warrant inducement transactions, equity line financings, and a 1-for-20 reverse stock split undertaken to support continued Nasdaq listing. For anyone monitoring antibiotic innovation against Gram-positive priority pathogens, the ACXP news page provides an organized view of Acurx’s clinical, regulatory, scientific and financing milestones over time.
Acurx (NASDAQ: ACXP) announced an Australian patent grant for DNA Polymerase IIIC inhibitors, adding to its global intellectual property that already includes three U.S. patents and patents in Israel, Japan and India.
The patent covers compositions of matter tied to the ACX-375C program. Management noted the lead DNA pol IIIC inhibitor is Phase 3-ready for oral C. difficile treatment, while new preclinical compounds are systemically absorbed for potential oral and parenteral use across indications including ABSSSI (MRSA), CABP, HABP/VABP, bacteremia/sepsis, endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax.
Acurx Pharmaceuticals (NASDAQ:ACXP) has received a positive opinion from the European Medicines Agency's (EMA) Paediatric Committee (PDCO) on its Pediatric Investigation Plan (PIP) for ibezapolstat in treating children with C. difficile infection (CDI). This marks a significant regulatory milestone as the company prepares for Phase 3 clinical trials.
The company has already secured FDA QIDP and Fast-Track Designation, along with EMA's SME designation. Both the FDA and EMA are aligned with Acurx's clinical trial program for adults, with clear regulatory pathways established for EU MAA and U.S. NDA submissions. The development addresses a critical need, as CDI affects 20,000 children annually, with a 20-30% recurrence rate.
Upon successful completion, ibezapolstat could receive 11 years of marketing exclusivity in Europe, including an additional year on top of the standard 10-year period for new antibiotics.
[ "Positive EMA opinion received for pediatric investigation plan (PIP)", "FDA QIDP and Fast-Track Designation already secured", "Potential for 11 years of marketing exclusivity in Europe", "Clear regulatory pathway established with both FDA and EMA", "Addresses significant unmet need in pediatric CDI treatment" ]Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company focused on developing novel antibiotics, has successfully regained compliance with Nasdaq's listing requirements. The company has met two critical criteria: maintaining a minimum bid price of $1.00 per share and achieving the minimum stockholders' equity threshold of $2.5 million.
This development ensures ACXP's continued listing and trading on the Nasdaq Stock Market, marking a significant milestone for the company's market presence and accessibility to investors.
Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company, reported its Q2 2025 financial results and business updates. The company ended Q2 with $6.1 million in cash, up from $3.7 million in December 2024. Key developments include securing an Indian patent for DNA polymerase IIIC inhibitors and establishing a $12 million equity line of credit with Lincoln Park Capital.
The company reported a reduced net loss of $2.2 million ($1.89 per share) in Q2 2025, compared to $4.1 million in Q2 2024. R&D expenses decreased to $0.5 million from $1.8 million year-over-year, while G&A expenses reduced to $1.7 million from $2.3 million. In August, ACXP implemented a 1-for-20 reverse stock split to maintain Nasdaq listing compliance.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced a 1-for-20 reverse stock split effective August 4, 2025, at 4:01 p.m. ET. The company's stock will begin trading on a split-adjusted basis on August 5, 2025, under the same ticker "ACXP" but with a new CUSIP number (00510M 203).
The reverse split will reduce outstanding shares from approximately 30.7 million to 1.5 million. The move aims to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement. Stockholders will receive cash payments for fractional shares based on the closing price on August 1, 2025.
Proportional adjustments will be made to stock options, warrants, and shares under incentive plans. Most shareholders won't need to take action, as positions will be automatically adjusted through their brokers.
Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections, has scheduled its Q2 2025 financial results conference call for August 12, 2025, at 8:00 AM ET. The company's leadership team, including CEO David P. Luci and CFO Robert G. Shawah, will host the call to discuss quarterly results and provide a business update.
Investors can access the call toll-free from the U.S. at 1-877-790-1503 using Conference ID: 13755161, with international dial-in numbers available through the company's conferencing system.